1997 Annual Report
Product Review Financials Setting  
  |Product Pipeline      
|Product Portfolio

| Cardiovascular Diseases | Central Nervous System Disorders | Infectious Diseases |
| Arthritis/Inflammation| Metabolic Diseases | Allergic Diseases |
| Cancer | Genitourinary/Sexual Health | Surgery/Interventional |
| Consumer Health/OTC | Animal Health |
 

MAJOR PFIZER PRODUCTS AND SELECTED CANDIDATES IN DEVELOPMENT
Central Nervous System Disorders
Current Products
Aricept (donepezil)2
(for Alzheimer’s disease)
Atarax/Vistaril
Navane
Sinequan
Zoloft (for depression, OCD, and panic disorder)
Zoloft [U.S.]
(for pediatric OCD)

 
Extensions / Additional Indications (last 12 months) Under Regulatory Review In Advanced-Stage Development
Zoloft
(for panic disorder)
Zoloft [U.S.]
(for pediatric OCD)
Zeldox (ziprasidone)
(for psychosis)
Zeldox Intramuscular
(IM form of ziprasidone)
(for agitated psychotic patients)
eletriptan
(for acute migraine)
Zoloft
(for PTSD)
Zoloft liquid oral concentration
Key: [U.S.]—U.S. only    [I]—International only (in at least one country)
No Key—Both U.S. and at least one other country


2Copromoted by Eisai and Pfizer; trademark of Eisai

  letter back top next
  Logo Imagemap
  intended for investors
  Advisory Information for Investors
  Copyright © 1997, 1998 Pfizer Inc All rights reserved.